599 patents currently held
51 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Dec 2026
Next term end
440
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2039 · High confidence
Also notable
Ends Aug 2039 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Oct 2035 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Jan 2039 · High confidence
GIP/GLP1 Agonist Compositions
US 11,357,820
Cited by 19 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Dose Detection for a Medication Delivery Device
US 11,541,186
Cited by 14 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Fusion Proteins and Methods of Use
US 10,709,766
Cited by 40 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
Display Screen with a Graphical User Interface
US D983,228
Cited by 21 later US patents, top 5% of design patents granted in 2023 in our data. Protection runs to 2038.
Anti-Cgrp Antibody Formulation
US 11,498,959
Cited by 18 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036.
Drug Delivery Device
US D898,900
Cited by 66 later US patents, top 5% of design patents granted in 2020 in our data. Protection runs to 2035.
Base for an Automatic Injection Device
US RE48,006
Cited by 32 later US patents, top 25% of design patents granted in 2020 in our data. Protection runs to 2035.
Incretin Analogs and Uses Thereof
US 11,542,313
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 6 fees due Dec 2 to 30, 2026 · next Dec 2
- 6 fees due Jan 7 to 30, 2027 · next Jan 7
- 5 fees due Feb 6 to 22, 2027 · next Feb 6
- 7 fees due Mar 1 to 29, 2027 · next Mar 1
- 10 fees due Apr 1 to 22, 2027 · next Apr 1
- 11 fees due May 5 to 28, 2027 · next May 5
- 10 fees due Jun 3 to 30, 2027 · next Jun 3
- 10 fees due Jul 2 to 30, 2027 · next Jul 2
- 9 fees due Aug 6 to 23, 2027 · next Aug 6
- 14 fees due Sep 3 to 30, 2027 · next Sep 3
- 9 fees due Oct 7 to 30, 2027 · next Oct 7
- 4 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- Nov 6Assignment recorded on 1 record: Arnett, Jaime R. and 1 other to Eli Lilly and Company Recorded Nov 6, 2026, executed Feb 4, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76667, frame 841.
- Oct 20Assignment recorded on 1 record: Bell, Michael Gregory to Eli Lilly and Company Recorded Oct 20, 2026, executed Dec 6, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76435, frame 500.
- 31 of the patents on this record were granted since Aug 21, 2026
- 4 terms have ended since Aug 21, 2026
What they patent
The largest of its 440 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Display Screen with a Graphical User Interface | 5 in force | to Sep 2040 |
| Dose Detection for a Medication Delivery Device | 5 in force | to Jul 2040 |
| GIP/GLP1 Agonist Compositions | 5 in force | to Jun 2039 |
| Label | 4 in force | to Feb 2041 |
| Medication Delivery Device with Sensing System | 4 in force | to Sep 2039 |
| Selective Estrogen Receptor Degraders | 4 in force | to Jul 2039 |
| Automatic Injecton Device and a Button Thereof | 4 in force | to Jun 2037 |
| Fusion Proteins | 4 in force | to Mar 2037 |
| Rapid-Acting Insulin Compositions | 4 in force | to Dec 2035 |
| Pan-ELR+ CXC CHEMOKINE ANTIBODIES | 4 in force | to Jun 2034 |
| Box | 3 in force | to Aug 2041 |
| Drug Delivery Device | 3 in force | to Sep 2040 |
| Gipr-Agonist Compounds | 3 in force | to Jul 2040 |
| KCNQ Potentiators | 3 in force | to Jun 2040 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,110,191 | ANTI-IL-17 Antibodies In force · High confidence | In force | High confidence | |
| US 7,696,248 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses In force · High confidence | In force | High confidence | |
| US 8,084,420 | Rapid Acting and Long Acting Insulin Combination Formulations In force · Medium confidence | In force | Medium confidence | |
| US 7,718,609 | Rapid Acting and Long Acting Insulin Combination Formulations In force · Medium confidence | In force | Medium confidence | |
| US 7,968,587 | Tetrahydrocyclopenta[b] Indole Compounds as Androgen Receptor Modulators In force · High confidence | In force | High confidence | |
| US 9,708,291 | Novel Intermediate and Process Useful in the Preparation of {2-[1-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-5-Pyridin-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-Chlorophenyl)-METHANONE In force · High confidence | In force | High confidence | |
| US 10,035,787 | Novel Intermediate and Process Useful in the Preparation of {2-[1-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-5-Pyridin-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-Chlorophenyl)-METHANONE In force · High confidence | In force | High confidence | |
| US 7,452,966 | GLP-1 Analog Fusion Proteins In force · Medium confidence | In force | Medium confidence | |
| US 7,918,824 | Needled Pharmaceutical Delivery Device with Triggered Automatic Needle Insertion and Manually Controlled Pharmaceutical Injection In force · High confidence | In force | High confidence | |
| US 8,409,138 | Delay Mechanism for Automatic Injection Device In force · High confidence | In force | High confidence |
Also on record, not counted in the 599: 51 patents in force now held by others · 610 patents ended · 389 applications pending · 416 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.